Press release
Xintela AB (publ)
556780-3480
2019-04-26

Xintela publishes results from glioblastoma study

Lund, Sweden, 26 April 2019 – Xintela announces that the results of the company's glioblastoma study have now been published in the renowned international scientific journal Cancers. The publication demonstrates and discusses that Xintela's marker, integrin α10β1, regulates important functions of glioblastoma cells and is a potential new therapeutic target for the treatment of the highly aggressive brain tumor glioblastoma.

Glioblastoma is the most common and most aggressive brain tumor form in adults and there is a enormous need for new and better treatment strategies. Xintela has previously reported positive preclinical results in which an antibody directed against the company's marker integrin α10β1 and combined with a cell toxin (Antibody-Drug Conjugate, ADC) was able to kill glioblastoma cells, both in cell experiments and in an animal model. The article now published, demonstrates that integrin α10β1 is highly expressed on cells in glioblastoma tumors but not in normal brain tissue and that the integrin has an important functional role on the glioblastoma cells by regulating cell migration (movement), growth and survival. In addition, the results show that an ADC directed to integrin α10β1 can block the function of glioblastoma cells and lead to the killing of the glioblastoma cells both in cell experiments and in an animal model. These results demonstrate the potential of the Xintela marker integrin α10β1 as a novel therapeutic target for the treatment of glioblastoma.

"We are very pleased that our results have now been published in the renowned international scientific journal Cancers. This is very positive in our discussions with potential investors and partners in the development of a First-in-Class therapy for glioblastoma and other high-grade, aggressive tumors", says Xintela's CEO Evy Lundgren-Åkerlund.

The publication:
Integrin α10, a Novel Therapeutic Target in Glioblastoma, Regulates Cell Migration, Proliferation, and Survival by Matilda Munksgaard Thorén, Katarzyna Chmielarska Masoumi, Cecilia Krona, Xiaoli Huang, Soumi Kundu, Linnéa Schmidt, Karin Forsberg-Nilsson, Marcus Floyd Keep, Elisabet Englund, Sven Nelander, Bo Holmqvist and Evy Lundgren-Åkerlund**.** Cancers 2019, 11(4), 587.

To read the publication, visit: https://doi.org/10.3390/cancers11040587

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy@xintela.se
Medicon Village
223 81 Lund
www.xintela.se

About Xintela
Xintela develops medical products within regenerative medicine and oncology based on its proprietary marker technology, XINMARK®. Xintela uses the technology to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis. Studies on horses have shown that the stem cells are safe and that they have a therapeutic effect on the articular cartilage and the underlying bone after an injury. Xintela has recently established its own GMP-facility to produce stem cells for clinical studies. In the oncology program, XINMARK® is used for the development of an antibody-based treatment (Antibody Drug Conjugate, ADC) against specific tumors with first focus on the aggressive brain tumor glioblastoma. Positive preclinical results from cell studies and animal model have shown that the ADC treatment has a targeting and killing effect on specific tumor cells supporting further development of the company's oncology business. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.